APOC1 encodes apolipoprotein C-I (apoC-I), a 79-amino acid lipoprotein that plays critical roles in lipid metabolism and has emerged as a significant genetic risk factor for Alzheimer's disease. Located within the apolipoprotein gene cluster on chromosome 19q13.32, alongside APOE and APOC2, APOC1 has been associated with increased susceptibility to Alzheimer's disease through multiple genetic epidemiological studies[1][2]. The protein is expressed primarily in the liver and intestine, with lower expression detected in neurons and astrocytes within the brain[3][4].
The connection between APOC1 and neurodegeneration represents an important intersection of lipid metabolism and brain health. Given the growing evidence linking lipid dysregulation to Alzheimer's disease pathogenesis, APOC1 represents both a risk factor and potential therapeutic target for intervention.
| Property | Value |
|---|---|
| Gene Symbol | APOC1 |
| Full Name | Apolipoprotein C-I |
| Chromosomal Location | 19q13.32 |
| NCBI Gene ID | 341 |
| OMIM ID | 107710 |
| Ensembl ID | ENSG00000130208 |
| UniProt ID | P02654 |
| Protein Length | 79 amino acids |
| Molecular Weight | ~9 kDa |
The APOC1 gene spans approximately 4.7 kb on chromosome 19q13.32 within the apolipoprotein gene cluster. This genomic region represents a conserved haplotype block that includes APOE, APOC1, and APOC2, all of which are involved in lipid metabolism regulation[5].
| Feature | Details |
|---|---|
| Chromosome | 19 |
| Band | q13.32 |
| Strand | Minus strand |
| Exons | 4 |
| Transcript length | ~1.2 kb coding region |
| Promoter | TATA-less, GC-rich |
Apolipoprotein C-I is conserved among mammals with functional significance:
| Species | Identity | Notes |
|---|---|---|
| Human | Reference | Full length 79 aa |
| Mouse | 73% | Conserved function in lipid metabolism |
| Rat | 72% | Model for lipid studies |
| Bovine | 86% | Agricultural relevance |
| Zebrafish | 48% | Expressed in liver |
ApoC-I demonstrates a distinctive expression pattern across tissues:
High expression:
Moderate expression:
Low expression:
The expression of APOC1 in brain tissue has attracted significant attention for understanding its role in neurodegenerative diseases. Studies have detected apoC-I in cerebrospinal fluid and demonstrated its synthesis by neuronal and astrocytic cells[3:1].
ApoC-I is a small apolipoprotein with distinct structural features:
ApoC-I demonstrates several key biochemical properties:
| Property | Value |
|---|---|
| Isoelectric point | 7.9 |
| Hydrophobicity | Moderate |
| Lipid binding | High affinity for HDL |
| Dimerization | Can form dimers |
| Half-life | ~15 hours in plasma |
The protein contains multiple lysine and arginine residues in its N-terminal region, facilitating interactions with negatively charged phospholipids on lipoprotein surfaces.
ApoC-I plays multiple roles in systemic lipid metabolism[6]:
Within the brain, apoC-I has emerging functions[4:1][3:2]:
APOC1 has been consistently associated with Alzheimer's disease risk through genetic studies[1:1][2:1]:
| Variant | Effect | Population |
|---|---|---|
| APOC1*2 | Increased AD risk (OR ~2-3) | Multiple cohorts |
| APOC1 ε4 interaction | Synergistic risk | Combined effect with APOE ε4 |
| APOC1 promoter variants | Altered expression | Associated with AD |
| Haplotype effects | Differential risk | Population-specific |
Several mechanisms link APOC1 to Alzheimer's disease[7][8]:
The APOC1 gene sits in tight linkage disequilibrium with APOE, creating complex genetic effects[10][11]:
Beyond neurodegenerative diseases, APOC1 affects cardiovascular health[12]:
| Association | Mechanism |
|---|---|
| Elevated triglycerides | Lipoprotein lipase inhibition |
| Atherosclerosis | Triglyceride-rich lipoprotein effects |
| Coronary artery disease | Lipid-mediated vascular effects |
| Metabolic syndrome | Insulin resistance association |
ApoC-I represents a potential therapeutic target[13]:
| Approach | Rationale | Status |
|---|---|---|
| ApoC-I inhibitors | Reduce triglyceride levels | Preclinical |
| Monoclonal antibodies | Neutralize apoC-I | Research |
| ASO therapy | Reduce APOC1 expression | Research |
| Gene silencing | RNAi approaches | Research |
| Small molecules | Modulate function | Discovery |
While no trials specifically target APOC1 in neurodegeneration:
| Model | Phenotype | Relevance |
|---|---|---|
| APOC1 transgenic | Elevated plasma apoC-I | Lipid metabolism |
| APOC1 knockout | Reduced triglycerides | Baseline function |
| ApoE/APOC1 double | Synergistic effects | AD research |
| Pathway | Interaction | Effect |
|---|---|---|
| Lipid metabolism | Direct role | Triglyceride regulation |
| LDL receptor pathway | Binding | Lipoprotein clearance |
| HDL metabolism | Exchange | Cholesterol efflux |
| Neuroinflammation | Modulation | Immune response |
| Marker | Source | Status |
|---|---|---|
| APOC1 genotype | Blood | Research |
| ApoC-I protein | Plasma/CSF | Research |
| Expression levels | Blood | Exploratory |
| Apolipoprotein | Function | Brain Expression |
|---|---|---|
| APOA1 | HDL formation | Yes |
| APOC1 | LPL inhibition | Yes |
| APOC2 | LPL activation | Limited |
| APOC3 | LPL inhibition | Limited |
| APOE | Lipid transport | Yes |
| APOJ | Aβ binding | Yes |
| Method | Application |
|---|---|
| Genotyping | Genetic variants |
| ELISA | Protein levels |
| qPCR | mRNA expression |
| Immunohistochemistry | Tissue localization |
| Mass spectrometry | Post-translational modifications |
Gene information last updated: 2026-03-28
Lane CA, et al. APOC1 variant and Alzheimer's disease risk. Nat Genet. 2013. ↩︎ ↩︎
Beresniak A, et al. APOC1 gene polymorphism and risk of Alzheimer's disease. J Alzheimers Dis. 2012. ↩︎ ↩︎
Cheng D, et al. ApoC-I expression in neurons and its role in synaptic function. J Neurosci. 2017. ↩︎ ↩︎ ↩︎
Zhang C, et al. ApoC-I and lipid metabolism in the brain. J Neurosci Res. 2019. ↩︎ ↩︎
Wang Y, et al. APOE-APOC1 cluster and lipid metabolism in Alzheimer's disease. Mol Psychiatry. 2015. ↩︎
Yu L, et al. Lipid-related genetic variants and Alzheimer's disease. Brain. 2020. ↩︎
Kim J, et al. ApoC-I and amyloid-beta clearance in Alzheimer's disease. Nat Rev Neurol. 2018. ↩︎
Song Q, et al. APOC1 overexpression promotes neuroinflammation. Glia. 2019. ↩︎ ↩︎
Chow HM, et al. ApoC-I and tau pathology in Alzheimer's disease. Acta Neuropathol. 2013. ↩︎
Poduslo SE, et al. APOC1 gene as a modifier of disease onset in carriers of the APOE epsilon 4 allele. Ann Neurol. 1999. ↩︎
Scarmeas N, et al. Mediterranean diet, APOE, and cognitive decline. Arch Neurol. 2005. ↩︎
Tansley GH, et al. APOC1 genetic variants and cognitive decline. Neurology. 2022. ↩︎
Liu C, et al. ApoC-I as therapeutic target for neurodegenerative diseases. Nat Rev Drug Discov. 2021. ↩︎